Altogether, these data suggest that the downregulation of WASP by BCR–ABL1 may be relevant to the CML prognosis, particularly for patients in advanced phases of disease. This evidence concerns the gene WAS and chronic myelogenous leukemia, BCR-ABL1 positive.